These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
159 related articles for article (PubMed ID: 18983537)
21. Role of p38 mitogen-activated protein kinase and extracellular signal-regulated protein kinase kinase in adenosine A2B receptor-mediated interleukin-8 production in human mast cells. Feoktistov I; Goldstein AE; Biaggioni I Mol Pharmacol; 1999 Apr; 55(4):726-34. PubMed ID: 10101031 [TBL] [Abstract][Full Text] [Related]
22. Celecoxib inhibits cell proliferation through the activation of ERK and p38 MAPK in head and neck squamous cell carcinoma cell lines. Park SW; Kim HS; Hah JW; Jeong WJ; Kim KH; Sung MW Anticancer Drugs; 2010 Oct; 21(9):823-30. PubMed ID: 20717005 [TBL] [Abstract][Full Text] [Related]
23. Phosphatase-mediated crosstalk control of ERK and p38 MAPK signaling in corneal epithelial cells. Wang Z; Yang H; Tachado SD; Capó-Aponte JE; Bildin VN; Koziel H; Reinach PS Invest Ophthalmol Vis Sci; 2006 Dec; 47(12):5267-75. PubMed ID: 17122112 [TBL] [Abstract][Full Text] [Related]
24. The BRAFV600E oncogene induces transforming growth factor beta secretion leading to sodium iodide symporter repression and increased malignancy in thyroid cancer. Riesco-Eizaguirre G; Rodríguez I; De la Vieja A; Costamagna E; Carrasco N; Nistal M; Santisteban P Cancer Res; 2009 Nov; 69(21):8317-25. PubMed ID: 19861538 [TBL] [Abstract][Full Text] [Related]
25. Role of the mitogen-activated protein kinase signaling pathway in the regulation of human melanocytic antigen expression. Kono M; Dunn IS; Durda PJ; Butera D; Rose LB; Haggerty TJ; Benson EM; Kurnick JT Mol Cancer Res; 2006 Oct; 4(10):779-92. PubMed ID: 17050671 [TBL] [Abstract][Full Text] [Related]
26. Functional status and relationships of melanocortin 1 receptor signaling to the cAMP and extracellular signal-regulated protein kinases 1 and 2 pathways in human melanoma cells. Herraiz C; Journé F; Ghanem G; Jiménez-Cervantes C; García-Borrón JC Int J Biochem Cell Biol; 2012 Dec; 44(12):2244-52. PubMed ID: 23000456 [TBL] [Abstract][Full Text] [Related]
27. Selective reduction of extracellular signal-regulated protein kinase (ERK) phosphorylation in squamous cell carcinoma of the larynx. Garavello W; Nicolini G; Aguzzi A; Maggioni D; Leone BE; Viganò P; Gaini RM; Tredici G Oncol Rep; 2006 Sep; 16(3):479-84. PubMed ID: 16865246 [TBL] [Abstract][Full Text] [Related]
28. Resistance to mitogen-activated protein kinase kinase (MEK) inhibitors correlates with up-regulation of the MEK/extracellular signal-regulated kinase pathway in hepatocellular carcinoma cells. Yip-Schneider MT; Klein PJ; Wentz SC; Zeni A; Menze A; Schmidt CM J Pharmacol Exp Ther; 2009 Jun; 329(3):1063-70. PubMed ID: 19258520 [TBL] [Abstract][Full Text] [Related]
29. Activation of extracellular signal-regulated kinase during silibinin-protected, isoproterenol-induced apoptosis in rat cardiac myocytes is tyrosine kinase pathway-mediated and protein kinase C-dependent. Zhou B; Wu LJ; Tashiro S; Onodera S; Uchiumi F; Ikejima T Acta Pharmacol Sin; 2007 Jun; 28(6):803-10. PubMed ID: 17506939 [TBL] [Abstract][Full Text] [Related]
31. Phospho-ERK staining is a poor indicator of the mutational status of BRAF and NRAS in human melanoma. Houben R; Vetter-Kauczok CS; Ortmann S; Rapp UR; Broecker EB; Becker JC J Invest Dermatol; 2008 Aug; 128(8):2003-12. PubMed ID: 18323787 [TBL] [Abstract][Full Text] [Related]
32. Coexpression of NRASQ61R and BRAFV600E in human melanoma cells activates senescence and increases susceptibility to cell-mediated cytotoxicity. Petti C; Molla A; Vegetti C; Ferrone S; Anichini A; Sensi M Cancer Res; 2006 Jul; 66(13):6503-11. PubMed ID: 16818621 [TBL] [Abstract][Full Text] [Related]
33. Activation of the MAPK pathway is a common event in uveal melanomas although it rarely occurs through mutation of BRAF or RAS. Zuidervaart W; van Nieuwpoort F; Stark M; Dijkman R; Packer L; Borgstein AM; Pavey S; van der Velden P; Out C; Jager MJ; Hayward NK; Gruis NA Br J Cancer; 2005 Jun; 92(11):2032-8. PubMed ID: 15928660 [TBL] [Abstract][Full Text] [Related]
34. Regulation of NR4A nuclear receptor expression by oncogenic BRAF in melanoma cells. Smith AG; Lim W; Pearen M; Muscat GE; Sturm RA Pigment Cell Melanoma Res; 2011 Jun; 24(3):551-63. PubMed ID: 21362156 [TBL] [Abstract][Full Text] [Related]
35. P38 MAPK Promotes Migration and Metastatic Activity of BRAF Mutant Melanoma Cells by Inducing Degradation of PMCA4b. Naffa R; Vogel L; Hegedűs L; Pászty K; Tóth S; Kelemen K; Singh N; Reményi A; Kállay E; Cserepes M; Tóvári J; Grusch M; Enyedi Á Cells; 2020 May; 9(5):. PubMed ID: 32414111 [TBL] [Abstract][Full Text] [Related]
36. BRAF somatic mutations in malignant melanoma and melanocytic naevi. Thomas NE Melanoma Res; 2006 Apr; 16(2):97-103. PubMed ID: 16567964 [TBL] [Abstract][Full Text] [Related]
37. Tumor-derived fibronectin is involved in melanoma cell invasion and regulated by V600E B-Raf signaling pathway. Gaggioli C; Robert G; Bertolotto C; Bailet O; Abbe P; Spadafora A; Bahadoran P; Ortonne JP; Baron V; Ballotti R; Tartare-Deckert S J Invest Dermatol; 2007 Feb; 127(2):400-10. PubMed ID: 16960555 [TBL] [Abstract][Full Text] [Related]
38. MFG-E8 inhibits neutrophil migration through αvβ₃-integrin-dependent MAP kinase activation. Aziz M; Yang WL; Corbo LM; Chaung WW; Matsuo S; Wang P Int J Mol Med; 2015 Jul; 36(1):18-28. PubMed ID: 25936372 [TBL] [Abstract][Full Text] [Related]
39. Signalling and chemosensitivity assays in melanoma: is mutated status a prerequisite for targeted therapy? Passeron T; Lacour JP; Allegra M; Ségalen C; Deville A; Thyss A; Giacchero D; Ortonne JP; Bertolotto C; Ballotti R; Bahadoran P Exp Dermatol; 2011 Dec; 20(12):1030-2. PubMed ID: 22092579 [TBL] [Abstract][Full Text] [Related]
40. Overexpression of collagenase 1 (MMP-1) is mediated by the ERK pathway in invasive melanoma cells: role of BRAF mutation and fibroblast growth factor signaling. Huntington JT; Shields JM; Der CJ; Wyatt CA; Benbow U; Slingluff CL; Brinckerhoff CE J Biol Chem; 2004 Aug; 279(32):33168-76. PubMed ID: 15184373 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]